Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting

Jan-Willem M Beenakker; Niels J Brouwer; Cindy Chau; Sarah E Coupland; Miltiadis Fiorentzis; Heinrich Heimann; Jens Heufelder; Antonia M Joussen; Jens F Kiilgaard; Tero T Kivelä; Sophie Piperno-Neumann; Elina S Rantala; Bozena Romanovska-Dixon; Carol L Shields; Gregor D Willerding; Thomas Wheeler-Schilling; Hendrik P N Scholl; Martine J Jager; Bertil E Damato

doi:10.1159/000524372

Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting

Jan-Willem M Beenakker^*, Niels J Brouwer, Cindy Chau, Sarah E Coupland, Miltiadis Fiorentzis, Heinrich Heimann, Jens Heufelder, Antonia M Joussen, Jens F Kiilgaard, Tero T Kivelä, Sophie Piperno-Neumann, Elina S Rantala, Bozena Romanovska-Dixon, Carol L Shields, Gregor D Willerding, Thomas Wheeler-Schilling, Hendrik P N Scholl, Martine J Jager, Bertil E Damato

^*Corresponding author for this work

Ophthalmology, Department of

Abstract

Uveal Melanoma (UM) is the most common primary intra-ocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "Outcome Measures of New Technologies in Uveal Melanoma", addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient's wellbeing. This review highlights the meeting's presentations in the context of the published literature.

Original language	English
Journal	Ophthalmic Research
Volume	66
Pages (from-to)	14-26
Number of pages	13
ISSN	0030-3747
DOIs	https://doi.org/10.1159/000524372
Publication status	Published - 2023

Access to Document

10.1159/000524372

Cite this

Beenakker, J-W. M., Brouwer, N. J., Chau, C., Coupland, S. E., Fiorentzis, M., Heimann, H., Heufelder, J., Joussen, A. M., Kiilgaard, J. F., Kivelä, T. T., Piperno-Neumann, S., Rantala, E. S., Romanovska-Dixon, B., Shields, C. L., Willerding, G. D., Wheeler-Schilling, T., Scholl, H. P. N., Jager, M. J., & Damato, B. E. (2023). Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting. Ophthalmic Research, 66, 14-26. https://doi.org/10.1159/000524372

Beenakker, J-WM, Brouwer, NJ, Chau, C, Coupland, SE, Fiorentzis, M, Heimann, H, Heufelder, J, Joussen, AM, Kiilgaard, JF, Kivelä, TT, Piperno-Neumann, S, Rantala, ES, Romanovska-Dixon, B, Shields, CL, Willerding, GD, Wheeler-Schilling, T, Scholl, HPN, Jager, MJ & Damato, BE 2023, 'Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting', Ophthalmic Research, vol. 66, pp. 14-26. https://doi.org/10.1159/000524372

@article{dd8c421feb524594b43581a49f860d34,

title = "Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting",

abstract = "Uveal Melanoma (UM) is the most common primary intra-ocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on {"}Outcome Measures of New Technologies in Uveal Melanoma{"}, addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient's wellbeing. This review highlights the meeting's presentations in the context of the published literature.",

author = "Beenakker, {Jan-Willem M} and Brouwer, {Niels J} and Cindy Chau and Coupland, {Sarah E} and Miltiadis Fiorentzis and Heinrich Heimann and Jens Heufelder and Joussen, {Antonia M} and Kiilgaard, {Jens F} and Kivel{\"a}, {Tero T} and Sophie Piperno-Neumann and Rantala, {Elina S} and Bozena Romanovska-Dixon and Shields, {Carol L} and Willerding, {Gregor D} and Thomas Wheeler-Schilling and Scholl, {Hendrik P N} and Jager, {Martine J} and Damato, {Bertil E}",

note = "The Author(s). Published by S. Karger AG, Basel.",

year = "2023",

doi = "10.1159/000524372",

language = "English",

volume = "66",

pages = "14--26",

journal = "Ophthalmic Research",

issn = "0030-3747",

publisher = "S./Karger AG",

}

TY - JOUR

T1 - Outcome Measures of New Technologies in Uveal Melanoma

T2 - Review from the European Vision Institute Special Interest Focus Group Meeting

AU - Beenakker, Jan-Willem M

AU - Brouwer, Niels J

AU - Chau, Cindy

AU - Coupland, Sarah E

AU - Fiorentzis, Miltiadis

AU - Heimann, Heinrich

AU - Heufelder, Jens

AU - Joussen, Antonia M

AU - Kiilgaard, Jens F

AU - Kivelä, Tero T

AU - Piperno-Neumann, Sophie

AU - Rantala, Elina S

AU - Romanovska-Dixon, Bozena

AU - Shields, Carol L

AU - Willerding, Gregor D

AU - Wheeler-Schilling, Thomas

AU - Scholl, Hendrik P N

AU - Jager, Martine J

AU - Damato, Bertil E

N1 - The Author(s). Published by S. Karger AG, Basel.

PY - 2023

Y1 - 2023

N2 - Uveal Melanoma (UM) is the most common primary intra-ocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "Outcome Measures of New Technologies in Uveal Melanoma", addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient's wellbeing. This review highlights the meeting's presentations in the context of the published literature.

AB - Uveal Melanoma (UM) is the most common primary intra-ocular tumor in adults. New diagnostic procedures and basic science discoveries continue to change our patient management paradigms. A recent meeting of the European Vision Institute (EVI) special interest focus group was held on "Outcome Measures of New Technologies in Uveal Melanoma", addressing the latest advances in UM, starting with genetic developments, then moving on to imaging and treatment of the primary tumor, as well as to investigating the most recent developments in treating metastases, and eventually taking care of the patient's wellbeing. This review highlights the meeting's presentations in the context of the published literature.

U2 - 10.1159/000524372

DO - 10.1159/000524372

M3 - Review

C2 - 35358966

VL - 66

SP - 14

EP - 26

JO - Ophthalmic Research

JF - Ophthalmic Research

SN - 0030-3747

ER -

Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting

Abstract

Access to Document

Fingerprint

Cite this